Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NYSE
Oaktree Acquisition Corp II (OACB)
Oaktree Acquisition Corp II (OACB) Actualités

OACB

Oaktree Acquisition Corp... (OACB)

Oaktree Acquisition Corp II

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NYSE:OACB

Date	Heure	Source	Titre	Symbole	Société
15/06/2022	17h36	Edgar (US Regulatory)	Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)	NYSE:OACB	Oaktree Acquisition Corp II
09/06/2022	13h10	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NYSE:OACB	Oaktree Acquisition Corp II
09/06/2022	03h16	Business Wire	Alvotech und Oaktree Acquisition Corp. II melden Zustimmung der Aktionäre zum Unternehmenszusammenschluss	NYSE:OACB	Oaktree Acquisition Corp II
08/06/2022	11h54	Business Wire	Alvotech et Oaktree Acquisition Corp. II annoncent l'approbation des actionnaires pour le regroupement d'entreprises	NYSE:OACB	Oaktree Acquisition Corp II
07/06/2022	22h00	Business Wire	Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination	NYSE:OACB	Oaktree Acquisition Corp II
03/06/2022	23h29	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:OACB	Oaktree Acquisition Corp II
03/06/2022	23h17	Business Wire	Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech	NYSE:OACB	Oaktree Acquisition Corp II
24/05/2022	13h00	Business Wire	Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®	NYSE:OACB	Oaktree Acquisition Corp II
16/05/2022	21h08	Edgar (US Regulatory)	Quarterly Report (10-q)	NYSE:OACB	Oaktree Acquisition Corp II
16/05/2022	14h00	Business Wire	Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®	NYSE:OACB	Oaktree Acquisition Corp II
11/05/2022	14h00	Business Wire	Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination	NYSE:OACB	Oaktree Acquisition Corp II
11/05/2022	00h34	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (definitive) (defm14a)	NYSE:OACB	Oaktree Acquisition Corp II
20/04/2022	23h00	Business Wire	Alvotech améliore son accès aux capitaux et optimise son processus d’entrée en bourse, prévue sur le NASDAQ	NYSE:OACB	Oaktree Acquisition Corp II
20/04/2022	18h45	Business Wire	Alvotech verbessert Zugang zu Kapital und ebnet Weg für erwartete NASDAQ-Notierung	NYSE:OACB	Oaktree Acquisition Corp II
20/04/2022	14h15	Business Wire	Alvotech migliora l'accesso al capitale e semplifica il percorso verso la prevista quotazione in Borsa al NASDAQ	NYSE:OACB	Oaktree Acquisition Corp II
20/04/2022	00h00	Business Wire	Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange	NYSE:OACB	Oaktree Acquisition Corp II
08/04/2022	16h01	Business Wire	アルヴォテックとSTADA、アッヴィとの欧州特許紛争を解決してHumira®のクエン酸フリー高濃度バイオシミラーHUKYNDRA®（AVT02）発売への道を開く	NYSE:OACB	Oaktree Acquisition Corp II
07/04/2022	03h15	Business Wire	Alvotech et STADA ouvrent la voie au lancement de HUKYNDRA® (AVT02), un biosimilaire de l'Humira® haute concentration sans citrate, en réglant le litige de brevet européen qui les opposait à AbbVie	NYSE:OACB	Oaktree Acquisition Corp II
07/04/2022	00h21	Business Wire	Alvotech und STADA ebnen durch Beilegung des europäischen Patentstreits mit AbbVie den Weg für die Markteinführung von HUKYNDRA®(AVT02), einem zitratfreien, hochkonzentrierten Biosimilar zu Humira®	NYSE:OACB	Oaktree Acquisition Corp II
06/04/2022	13h00	Business Wire	Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie	NYSE:OACB	Oaktree Acquisition Corp II
14/03/2022	12h10	Business Wire	アルヴォテックがアッヴィとの米国特許・企業秘密紛争を解決し、Humira®向けにアルヴォテックが提案中の高濃度バイオシミラー（AVT02）の米国での権利を確保	NYSE:OACB	Oaktree Acquisition Corp II
09/03/2022	23h44	Business Wire	Alvotech legt US-Patent- und Geschäftsgeheimnisstreitigkeiten mit AbbVie bei und sichert sich US-Rechte für von Alvotech geplantes hochkonzentriertes Biosimilar (AVT02) zu Humira®	NYSE:OACB	Oaktree Acquisition Corp II
09/03/2022	18h03	Business Wire	Alvotech règle les litiges portant sur des brevets et des secrets commerciaux qui l’opposaient à AbbVie aux États-Unis et garantit ainsi les droits américains pour le biosimilaire à l’Humira® haute concentration (AVT02) proposé par Alvotech	NYSE:OACB	Oaktree Acquisition Corp II
08/03/2022	23h06	Business Wire	Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech’s Proposed High-Concentration Biosimilar (AVT02) for Humira®	NYSE:OACB	Oaktree Acquisition Corp II
16/02/2022	22h14	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NYSE:OACB	Oaktree Acquisition Corp II
07/02/2022	22h46	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NYSE:OACB	Oaktree Acquisition Corp II
20/01/2022	16h15	Business Wire	Alvotech augmente le montant de transaction PIPE sursouscrite qui s’approche désormais de 175 millions USD	NYSE:OACB	Oaktree Acquisition Corp II
19/01/2022	17h18	Business Wire	Alvotech vergrößert überzeichnete PIPE-Transaktion auf ca. 175 Mio. USD	NYSE:OACB	Oaktree Acquisition Corp II
18/01/2022	22h01	Business Wire	Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million	NYSE:OACB	Oaktree Acquisition Corp II
13/12/2021	22h10	Edgar (US Regulatory)	Amended Quarterly Report (10-q/a)	NYSE:OACB	Oaktree Acquisition Corp II

Showing the most relevant articles for your search:NYSE:OACB

Cie de SaintGobain

Societe Generale

Credit Agricole

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales